Compare BioNTech SE - ADR (BNTX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vanguard Information Technology Index Fund ETF — how do they compare? BioNTech SE - ADR trades at $91.9 (market cap $22.86B), while Vanguard Information Technology Index Fund ETF trades at $116.23. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | VGT | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $125.77 |
52-Week Low | $83.89 | $83.59 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
VGT trades at $115.58, down 2.12% on the day amid a neutral technical signal. The ETF's moving averages show bearish momentum, while oscillators are neutral. Recent news highlights strong 2026 performance against the S&P 500 and ongoing investor interest in tech ETFs, though fee comparisons with competitors like FTEC are noted. A 1:8 stock split occurred in April 2026, with a small dividend scheduled for June 2026.
Outlook remains tied to tech sector strength and AI-driven earnings, but risks include valuation sensitivity and sector volatility. The ETF's low expense ratio and broad diversification offer a cost-effective tech exposure, yet overlap costs and hyperscaler capex guidance in H2 2026 warrant monitoring for potential pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
